Theriva Biologics has announced significant advancements in its research on cancer treatments, focusing on VCN-12, a next-generation oncolytic adenovirus. This candidate, developed from the lead product VCN-01, features a novel mechanism of action that could significantly enhance anti-tumor effects. The company plans to announce these findings during the 32nd Annual Congress of the European Society of Gene and Cell Therapy, taking place in Seville from October 7 to 10, 2025.
Dr. Ramón Alemany, co-founder of VCN Biosciences and leader of the Immunotherapy and Virotherapy Group at the Catalan Institute of Oncology, will present information on VCN-12 at this prominent event. This adenovirus has been engineered with additional transgenes, which optimize its ability to target tumor cells, facilitate the degradation of tumor stroma, and enhance the anti-tumor immune response.
The presentation is scheduled for Wednesday, October 8, 2025, in the Paralela B room at the Seville Congress and Exhibition Center. During the session, mechanistic and preclinical findings supporting the viability of VCN-12 as a treatment option for cancer will be shared.
Additionally, the announcement will include the publication of a monograph preceding the congress that discusses a study conducted by the University of Navarra. This study examines the intracranial administration of VCN-01 in the treatment of brain tumors, highlighting the urgent need for new therapies in this field. Researchers suggest that the study’s results provide a strong justification for continuing the development of VCN-01.
Theriva Biologics specializes in creating innovative therapies for cancer and other relevant diseases. Among its leading candidates are SYN-004 and SYN-020, designed to improve gastrointestinal health and anti-tumor response, respectively.
These research advancements represent a beacon of hope for many individuals facing cancer, underscoring the need to continue exploring and developing new therapeutic options in a challenging landscape.
Source: MiMub in Spanish